Ceftazidime-avibactam
- Autores: Francisco Sanz Herrero
- Localización: Revista Española de Quimioterapia, ISSN-e 0214-3429, Vol. 35, Nº Extra 1, 2022, págs. 40-42
- Idioma: inglés
- Enlaces
-
Resumen
The increase in nosocomial infections by beta-lactamaseproducing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa, and other enterobacteria. Compared to carbapenems, ceftazidime-avibactam has demonstrated non-inferiority in the treatment of nosocomial pneumonia including better clinical and microbiological cure rates and mortality compared to colistin. The limitation of ceftazidime-avibactam in the treatment of infections caused by metallo-beta-lactamase-producing Enterobacteriaceae can be overcome with the addition of aztreonam.